Leora Horn, M.D.

Associate Professor

Faculty Appointments
Associate Professor of Medicine Ingram Associate Professor of Cancer Research
M.D., University of Toronto, Toronto, CanadaM.S., University of Toronto, Toronto, CanadaB.S., University of Toronto, Toronto, Canada
Research Description
Leora Horn, MD, MSc, FRCPC is an Ingram Associate Professor of Cancer Research at Vanderbilt Ingram Cancer Center and Associate Professor of Medicine in the Division of Hematology/Oncology at the Vanderbilt University Medical Center. Dr Horn received her Honors Bachelor of Science and Masters of Science in Pharmacology from the University of Toronto where she also attended medical school and trained in internal medicine and medical oncology. She completed a sub-specialty fellowship in Thoracic Oncology at Vanderbilt University. Her fellowship was funded by an award from the Canadian Association of Medical Oncology.

Dr Horn's clinical practice focuses primarily on the care of patients with lung cancer. She is the Clinical Director of the Thoracic Oncology Program at Vanderbilt-Ingram Cancer Center. Her research interests include experimental therapeutics and medical education. Her work has been recognized with a VICC Impact award annually for the last eight years for her research contributions made to the Cancer Center.

Dr Horn is currently completing a Masters in Health Professional Education through the University of Illinois Chicago and is the Assistant Vice Chairman for Faculty Development in the Department of Medicine where she runs the Schaffner Society to support the careers of clinician educators in the Department of Medicine.

Clinical Description
Dr Horn is Principal Investigator on several lung cancer clinical trials and educational projects. She has published over 100 papers and book chapters including original papers, reviews and the recent chapter on "neoplasms of the Lung" in Harrison's Principles of Internal Medicine, 18th edition. She is an active member in the American Society of Clinical Oncology, the International Association for the Study of Lung Cancer, and the Royal College of Physicians and Surgeons of Canada.
Singhi EK, Horn L. Background and rationale of the eXalt3 trial investigating X-396 in the treatment of ALK+ non-small-cell lung cancer. Future Oncol [print-electronic]. 2018 Aug; 14(18): 1781-7. PMID: 29506392, DOI: 10.2217/fon-2017-0619, ISSN: 1744-8301.

Horn L, Gettinger SN, Gordon MS, Herbst RS, Gandhi L, Felip E, Sequist LV, Spigel DR, Antonia SJ, Balmanoukian A, Cassier PA, Liu B, Kowanetz M, O'Hear C, Fassò M, Grossman W, Sandler A, Soria JC. Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study. Eur. J. Cancer [print-electronic]. 2018 Aug 8/1/2018; 101: 201-9. PMID: 30077125, PII: S0959-8049(18)30945-6, DOI: 10.1016/j.ejca.2018.06.031, ISSN: 1879-0852.

Gerber DE, Horn L, Boyer M, Sanborn R, Natale R, Palmero R, Bidoli P, Bondarenko I, Germonpre P, Ghizdavescu D, Kotsakis A, Lena H, Losonczy G, Park K, Su WC, Tang M, Lai J, Kallinteris NL, Shan JS, Reck M, Spigel DR. Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer. Ann. Oncol. 2018 Jul 7/1/2018; 29(7): 1548-53. PMID: 29767677, PII: 4996069, DOI: 10.1093/annonc/mdy177, ISSN: 1569-8041.

Ettinger DS, Aisner DL, Wood DE, Akerley W, Bauman J, Chang JY, Chirieac LR, D'Amico TA, Dilling TJ, Dobelbower M, Govindan R, Gubens MA, Hennon M, Horn L, Lackner RP, Lanuti M, Leal TA, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Patel SP, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018. J Natl Compr Canc Netw. 2018 Jul; 16(7): 807-21. PMID: 30006423, PII: 16/7/807, DOI: 10.6004/jnccn.2018.0062, ISSN: 1540-1413.

Horn L, Infante JR, Reckamp KL, Blumenschein GR, Leal TA, Waqar SN, Gitlitz BJ, Sanborn RE, Whisenant JG, Du L, Neal JW, Gockerman JP, Dukart G, Harrow K, Liang C, Gibbons JJ, Holzhausen A, Lovly CM, Wakelee HA. Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study. Clin. Cancer Res [print-electronic]. 2018 Jun 6/15/2018; 24(12): 2771-9. PMID: 29563138, PMCID: PMC6004248, PII: 1078-0432.CCR-17-2398, DOI: 10.1158/1078-0432.CCR-17-2398, ISSN: 1078-0432.

Gettinger S, Horn L, Jackman D, Spigel D, Antonia S, Hellmann M, Powderly J, Heist R, Sequist LV, Smith DC, Leming P, Geese WJ, Yoon D, Li A, Brahmer J. Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study. J. Clin. Oncol [print-electronic]. 2018 Jun 6/10/2018; 36(17): 1675-84. PMID: 29570421, DOI: 10.1200/JCO.2017.77.0412, ISSN: 1527-7755.

Waterhouse D, Horn L, Reynolds C, Spigel D, Chandler J, Mekhail T, Mohamed M, Creelan B, Blankstein KB, Nikolinakos P, McCleod MJ, Li A, Oukessou A, Agrawal S, Aanur N. Safety profile of nivolumab administered as 30-min infusion: analysis of data from CheckMate 153. Cancer Chemother. Pharmacol [print-electronic]. 2018 Apr; 81(4): 679-86. PMID: 29442139, PII: 10.1007/s00280-018-3527-6, DOI: 10.1007/s00280-018-3527-6, ISSN: 1432-0843.

Vokes EE, Ready N, Felip E, Horn L, Burgio MA, Antonia SJ, Arén Frontera O, Gettinger S, Holgado E, Spigel D, Waterhouse D, Domine M, Garassino M, Chow LQM, Blumenschein G, Barlesi F, Coudert B, Gainor J, Arrieta O, Brahmer J, Butts C, Steins M, Geese WJ, Li A, Healey D, Crinò L. Nivolumab versus docetaxel in previously treated advanced non-small cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases. Ann. Oncol [print-electronic]. 2018 Feb 2/2/2018; PMID: 29408986, PII: 4835443, DOI: 10.1093/annonc/mdy041, ISSN: 1569-8041.

Almodovar K, Iams WT, Meador CB, Zhao Z, York S, Horn L, Yan Y, Hernandez J, Chen H, Shyr Y, Lim LP, Raymond CK, Lovly CM. Longitudinal Cell-Free DNA Analysis in Patients with Small Cell Lung Cancer Reveals Dynamic Insights into Treatment Efficacy and Disease Relapse. J Thorac Oncol [print-electronic]. 2018 Jan; 13(1): 112-23. PMID: 28951314, PII: S1556-0864(17)32705-3, DOI: 10.1016/j.jtho.2017.09.1951, ISSN: 1556-1380.

Lewis J, Gillaspie EA, Osmundson EC, Horn L. Before or After: Evolving Neoadjuvant Approaches to Locally Advanced Non-Small Cell Lung Cancer. Front Oncol. 2018; 8: 5. PMID: 29410947, PMCID: PMC5787144, DOI: 10.3389/fonc.2018.00005, ISSN: 2234-943X.

Yu HA, Spira A, Horn L, Weiss J, West H, Giaccone G, Evans T, Kelly RJ, Desai B, Krivoshik A, Moran D, Poondru S, Jie F, Aoyama K, Keating A, Oxnard GR. A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non-small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations. Clin. Cancer Res [print-electronic]. 2017 Dec 12/15/2017; 23(24): 7467-73. PMID: 28954786, PII: 1078-0432.CCR-17-1447, DOI: 10.1158/1078-0432.CCR-17-1447, ISSN: 1078-0432.

Horn L, Spigel DR, Vokes EE, Holgado E, Ready N, Steins M, Poddubskaya E, Borghaei H, Felip E, Paz-Ares L, Pluzanski A, Reckamp KL, Burgio MA, Kohlhäeufl M, Waterhouse D, Barlesi F, Antonia S, Arrieta O, Fayette J, Crinò L, Rizvi N, Reck M, Hellmann MD, Geese WJ, Li A, Blackwood-Chirchir A, Healey D, Brahmer J, Eberhardt WEE. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). J. Clin. Oncol [print-electronic]. 2017 Dec 12/10/2017; 35(35): 3924-33. PMID: 29023213, DOI: 10.1200/JCO.2017.74.3062, ISSN: 1527-7755.

Wakelee HA, Dahlberg SE, Keller SM, Tester WJ, Gandara DR, Graziano SL, Adjei AA, Leighl NB, Aisner SC, Rothman JM, Patel JD, Sborov MD, McDermott SR, Perez-Soler R, Traynor AM, Butts C, Evans T, Shafqat A, Chapman AE, Kasbari SS, Horn L, Ramalingam SS, Schiller JH, . Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol [print-electronic]. 2017 Dec; 18(12): 1610-23. PMID: 29129443, PMCID: PMC5789803, PII: S1470-2045(17)30691-5, DOI: 10.1016/S1470-2045(17)30691-5, ISSN: 1474-5488.

Horn L, Gettinger S, Camidge DR, Smit EF, Janjigian YY, Miller VA, Pao W, Freiwald M, Fan J, Wang B, Chand VK, Groen HJM. Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib. Lung Cancer [print-electronic]. 2017 Nov; 113: 51-8. PMID: 29110849, PII: S0169-5002(17)30487-7, DOI: 10.1016/j.lungcan.2017.08.014, ISSN: 1872-8332.

Byers LA, Horn L, Ghandi J, Kloecker G, Owonikoko T, Waqar SN, Krzakowski M, Cardnell RJ, Fujimoto J, Taverna P, Azab M, Camidge DR. A phase 2, open-label, multi-center study of amuvatinib in combination with platinum etoposide chemotherapy in platinum-refractory small cell lung cancer patients. Oncotarget. 2017 Oct 10/6/2017; 8(46): 81441-54. PMID: 29113403, PMCID: PMC5655298, PII: 19888, DOI: 10.18632/oncotarget.19888, ISSN: 1949-2553.

Ou SI, Horn L, Cruz M, Vafai D, Lovly CM, Spradlin A, Williamson MJ, Dagogo-Jack I, Johnson A, Miller VA, Gadgeel S, Ali SM, Schrock AB. Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patients. Lung Cancer [print-electronic]. 2017 Sep; 111: 61-4. PMID: 28838400, PII: S0169-5002(17)30385-9, DOI: 10.1016/j.lungcan.2017.07.006, ISSN: 1872-8332.

Soo RA, Stone ECA, Cummings KM, Jett JR, Field JK, Groen HJM, Mulshine JL, Yatabe Y, Bubendorf L, Dacic S, Rami-Porta R, Detterbeck FC, Lim E, Asamura H, Donington J, Wakelee HA, Wu YL, Higgins K, Senan S, Solomon B, Kim DW, Johnson M, Yang JCH, Sequist LV, Shaw AT, Ahn MJ, Costa DB, Patel JD, Horn L, Gettinger S, Peters S, Wynes MW, Faivre-Finn C, Rudin CM, Tsao A, Baas P, Kelly RJ, Leighl NB, Scagliotti GV, Gandara DR, Hirsch FR, Spigel DR. Scientific Advances in Thoracic Oncology 2016. J Thorac Oncol [print-electronic]. 2017 Aug; 12(8): 1183-209. PMID: 28579481, PII: S1556-0864(17)30427-6, DOI: 10.1016/j.jtho.2017.05.019, ISSN: 1556-1380.

Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, Felip E, van den Heuvel MM, Ciuleanu TE, Badin F, Ready N, Hiltermann TJN, Nair S, Juergens R, Peters S, Minenza E, Wrangle JM, Rodriguez-Abreu D, Borghaei H, Blumenschein GR, Villaruz LC, Havel L, Krejci J, Corral Jaime J, Chang H, Geese WJ, Bhagavatheeswaran P, Chen AC, Socinski MA, . First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2017 Jun 6/22/2017; 376(25): 2415-26. PMID: 28636851, DOI: 10.1056/NEJMoa1613493, ISSN: 1533-4406.

Arneson K, Mondschein J, Stavas M, Cmelak AJ, Attia A, Horn L, Niermann K, Puzanov I, Chakravarthy AB, Xia F. A phase I trial of concurrent sorafenib and stereotactic radiosurgery for patients with brain metastases. J. Neurooncol [print-electronic]. 2017 Jun; 133(2): 435-42. PMID: 28488066, PII: 10.1007/s11060-017-2455-3, DOI: 10.1007/s11060-017-2455-3, ISSN: 1573-7373.

Heist RS, Guarino MJ, Masters G, Purcell WT, Starodub AN, Horn L, Scheff RJ, Bardia A, Messersmith WA, Berlin J, Ocean AJ, Govindan SV, Maliakal P, Mudenda B, Wegener WA, Sharkey RM, Goldenberg DM, Camidge DR. Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan. J. Clin. Oncol [print-electronic]. 2017 May 5/26/2017; JCO2016721894. PMID: 28548889, DOI: 10.1200/JCO.2016.72.1894, ISSN: 1527-7755.

Castellanos E, Feld E, Horn L. Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non-Small Cell Lung Cancer. J Thorac Oncol [print-electronic]. 2017 Apr; 12(4): 612-23. PMID: 28017789, PII: S1556-0864(16)33604-8, DOI: 10.1016/j.jtho.2016.12.014, ISSN: 1556-1380.

Hui R, Garon EB, Goldman JW, Leighl NB, Hellmann MD, Patnaik A, Gandhi L, Eder JP, Ahn MJ, Horn L, Felip E, Carcereny E, Rangwala R, Lubiniecki GM, Zhang J, Emancipator K, Roach C, Rizvi NA. Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial. Ann. Oncol. 2017 Apr 4/1/2017; 28(4): 874-81. PMID: 28168303, PII: 2972135, DOI: 10.1093/annonc/mdx008, ISSN: 1569-8041.

Pelosof L, Ahn C, Gao A, Horn L, Madrigales A, Cox J, McGavic D, Minna JD, Gazdar AF, Schiller J. Proportion of Never-Smoker Non-Small Cell Lung Cancer Patients at Three Diverse Institutions. J. Natl. Cancer Inst [electronic-print]. 2017 Jan; 109(7): PMID: 28132018, PII: djw295, DOI: 10.1093/jnci/djw295, ISSN: 1460-2105.

Feld E, Horn L. Emerging role of nivolumab in the management of patients with non-small-cell lung cancer: current data and future perspectives. Onco Targets Ther. 2017; 10: 3697-708. PMID: 28769573, PMCID: PMC5533488, PII: ott-10-3697, DOI: 10.2147/OTT.S97903, ISSN: 1178-6930.

Iams WT, Yu H, Shyr Y, Patil T, Horn L, McCoach C, Kelly K, Doebele R, Camidge DR. PS01.68: Heterogeneous Clinical Syndromes Existing Within Patients with Stage IV KRAS Mutant Non-Small Cell Lung Cancer: Topic: Medical Oncology. J Thorac Oncol [print-electronic]. 2016 Nov; 11(11S): S313. PMID: 27969535, PII: S1556-0864(16)31052-8, DOI: 10.1016/j.jtho.2016.09.103, ISSN: 1556-1380.

Gordon MS, Herbst RS, Horn L, Soria JC, Gandhi L, Felip E, Sequist L, Spigel DR, Antonia SJ, Balmanoukian A, Cassier P, Liu B, Kowanetz M, O'Hear C, Fassò M, Sandler A, Gettinger SN. PS01.62: Long-Term Safety and Clinical Activity of Atezolizumab Monotherapy in Metastatic NSCLC: Final Results from a Phase Ia Study: Topic: Medical Oncology. J Thorac Oncol [print-electronic]. 2016 Nov; 11(11S): S309-S310. PMID: 27969529, PII: S1556-0864(16)31046-2, DOI: 10.1016/j.jtho.2016.09.097, ISSN: 1556-1380.

Horn L, Reck M, Mok T, Johnson ML, Tang X, Lam S, Waterkamp D, Lopez-Chavez A, Sandler A, Giacconne G, Liu SV. PS01.57: IMpower133: a Phase I/III Study of 1L Atezolizumab with Carboplatin and Etoposide in Patients with Extensive-Stage SCLC: Topic: Medical Oncology. J Thorac Oncol [print-electronic]. 2016 Nov; 11(11S): S305-S306. PMID: 27969524, PII: S1556-0864(16)31041-3, DOI: 10.1016/j.jtho.2016.09.092, ISSN: 1556-1380.

Feld E, Horn L, Phillips S. PS01.03: Referral Practices of Medical Oncologists to Palliative Care for Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC): Topic: Medical Oncology. J Thorac Oncol [print-electronic]. 2016 Nov; 11(11S): S271. PMID: 27969471, PII: S1556-0864(16)30988-1, DOI: 10.1016/j.jtho.2016.09.039, ISSN: 1556-1380.

Horn L, Wakelee H, Reckamp KL, Blumenschein G, Infante JR, Carter CA, Waqar SN, Neal JW, Harrow K, Gockerman JP, Dukart G, Liang C, Gibbons JL, Hernandez J, Newman-Eerkes T, Lim L, Lovly CM. MINI01.02: Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (pts) with ALK+ NSCLC: Topic: Medical Oncology. J Thorac Oncol [print-electronic]. 2016 Nov; 11(11S): S256-S257. PMID: 27969449, PII: S1556-0864(16)30966-2, DOI: 10.1016/j.jtho.2016.09.017, ISSN: 1556-1380.

Chiappori AA, Otterson GA, Dowlati A, Traynor AM, Horn L, Owonikoko TK, Ross HJ, Hann CL, Abu Hejleh T, Nieva J, Zhao X, Schell M, Sullivan DM. A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer. Oncologist [print-electronic]. 2016 Oct; 21(10): 1163-4. PMID: 27694157, PMCID: PMC5061534, PII: theoncologist.2016-0220, DOI: 10.1634/theoncologist.2016-0220, ISSN: 1549-490X.

Ramalingam S, Hui R, Gandhi L, Carcereny E, Felip E, Ahn MJ, Eder JP, Balmanoukian AS, Leighl N, Aggarwal C, Horn L, Patnaik A, Middleton GW, Gubens M, Hellmann M, Soria JC, Lubiniecki GM, Zhang J, Piperdi B, Garon EB. P2.39: Long-Term OS for Patients With Advanced NSCLC Enrolled in the KEYNOTE-001 Study of Pembrolizumab: Track: Immunotherapy. J Thorac Oncol [print-electronic]. 2016 Oct; 11(10S): S241-S242. PMID: 27676573, PII: S1556-0864(16)30819-X, DOI: 10.1016/j.jtho.2016.08.110, ISSN: 1556-1380.

Borghaei H, Brahmer J, Horn L, Ready N, Steins M, Felip E, Paz-Ares L, Xx X, Barlesi F, Antonia S, Fayette J, Rizvi N, Crino L, Reck M, Erich Eberhardt WE, Hellmann M, Desai K, Li A, Healey D, Spigel D, Mathias C. P2.35: Nivolumab vs Docetaxel in Advanced NSCLC: CheckMate 017/057 2-Y Update and Exploratory Cytokine Profile Analysis: Track: Immunotherapy. J Thorac Oncol [print-electronic]. 2016 Oct; 11(10S): S237-S238. PMID: 27676569, PII: S1556-0864(16)30815-2, DOI: 10.1016/j.jtho.2016.08.106, ISSN: 1556-1380.

Waterhouse D, Horn L, Reynolds C, Spigel D, Chandler J, Mekhail T, Mohamed M, Creelan B, Blankstein KB, Nikolinakos P, Mccleod MJ, Li A, Waxman IM, Aanur N, Agrawal S, Richardet E. P2.33: Safety Profile of Nivolumab Administered as 30-Minute (MIN) Infusion: Analysis of Data From Checkmate 153: Track: Immunotherapy. J Thorac Oncol [print-electronic]. 2016 Oct; 11(10S): S236. PMID: 27676567, PII: S1556-0864(16)30813-9, DOI: 10.1016/j.jtho.2016.08.104, ISSN: 1556-1380.

Leal T, Wakelee H, Infante J, Blumenschein G, Reckamp K, Carter C, Waqar S, Gockerman J, Lovly C, Dukart G, Harrow K, Liang C, Gibbons J, Horn L. P1.44 (also presented as PD2.02): Phase I/II Trial of X-396, A Novel ALK Inhibitor, in Patients With ALK+ NSCLC: Track: Advanced NSCLC. J Thorac Oncol [print-electronic]. 2016 Oct; 11(10S): S209-S210. PMID: 27676529, PII: S1556-0864(16)30775-4, DOI: 10.1016/j.jtho.2016.08.066, ISSN: 1556-1380.

Leal T, Wakelee H, Infante J, Blumenschein G, Reckamp K, Carter C, Waqar S, Gockerman J, Lovly C, Dukart G, Harrow K, Liang C, Gibbons J, Horn L. PD2.02 (also presented as P1.44): Phase I/II Trial of X-396, a Novel ALK Inhibitor, in Patients With ALK+ NSCLC. J Thorac Oncol [print-electronic]. 2016 Oct; 11(10S): S176-S177. PMID: 27676483, PII: S1556-0864(16)30726-2, DOI: 10.1016/j.jtho.2016.08.017, ISSN: 1556-1380.

Waqar SN, Bonomi PD, Govindan R, Hirsch FR, Riely GJ, Papadimitrakopoulou V, Kazandjian D, Khozin S, Larkins E, Dickson DJ, Malik S, Horn L, Ferris A, Shaw AT, Jänne PA, Mok TS, Herbst R, Keegan P, Pazdur R, Blumenthal GM. Clinician Perspectives on Current Issues in Lung Cancer Drug Development. J Thorac Oncol [print-electronic]. 2016 Sep; 11(9): 1387-96. PMID: 27401214, PMCID: PMC5131641, PII: S1556-0864(16)30459-2, DOI: 10.1016/j.jtho.2016.05.009, ISSN: 1556-1380.

Horn L, Reck M, Spigel DR. The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer. Oncologist [print-electronic]. 2016 Aug; 21(8): 910-21. PMID: 27354668, PMCID: PMC4978554, PII: theoncologist.2015-0523, DOI: 10.1634/theoncologist.2015-0523, ISSN: 1549-490X.

Reck M, Luft A, Szczesna A, Havel L, Kim SW, Akerley W, Pietanza MC, Wu YL, Zielinski C, Thomas M, Felip E, Gold K, Horn L, Aerts J, Nakagawa K, Lorigan P, Pieters A, Kong Sanchez T, Fairchild J, Spigel D. Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer. J. Clin. Oncol [print-electronic]. 2016 Jul 7/25/2016; PMID: 27458307, PII: JCO.2016.67.6601, DOI: 10.1200/JCO.2016.67.6601, ISSN: 1527-7755.

Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Dilling T, Dobelbower M, Govindan R, Hennon M, Horn L, Jahan TM, Komaki R, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Sharma N, Swanson SJ, Stevenson J, Tauer K, Yang SC, Gregory K, Hughes M. NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016. J Natl Compr Canc Netw. 2016 Jul; 14(7): 825-36. PMID: 27407123, PII: 14/7/825, ISSN: 1540-1413.

Antonia SJ, López-Martin JA, Bendell J, Ott PA, Taylor M, Eder JP, Jäger D, Pietanza MC, Le DT, de Braud F, Morse MA, Ascierto PA, Horn L, Amin A, Pillai RN, Evans J, Chau I, Bono P, Atmaca A, Sharma P, Harbison CT, Lin CS, Christensen O, Calvo E. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol [print-electronic]. 2016 Jul; 17(7): 883-95. PMID: 27269741, PII: S1470-2045(16)30098-5, DOI: 10.1016/S1470-2045(16)30098-5, ISSN: 1474-5488.

Feld E, Horn L. Targeting PD-L1 for non-small-cell lung cancer. Immunotherapy. 2016 Jun; 8(6): 747-58. PMID: 27197542, DOI: 10.2217/imt-2016-0012, ISSN: 1750-7448.

Lilenbaum RA, Horn LA. Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer. J Natl Compr Canc Netw. 2016 May; 14(5 Suppl): 672-4. PMID: 27226511, PII: 14/5S/672, ISSN: 1540-1413.

Chatterjee M, Turner DC, Felip E, Lena H, Cappuzzo F, Horn L, Garon EB, Hui R, Arkenau HT, Gubens MA, Hellmann MD, Dong D, Li C, Mayawala K, Freshwater T, Ahamadi M, Stone J, Lubiniecki GM, Zhang J, Im E, De Alwis DP, Kondic AG, Fløtten Ø. Systematic evaluation of pembrolizumab dosing in patients with advanced non-small cell lung cancer. Ann. Oncol [print-electronic]. 2016 Apr 4/26/2016; PMID: 27117531, PII: mdw174, DOI: 10.1093/annonc/mdw174, ISSN: 1569-8041.

Castellanos EH, Horn L. Re-Evaluating Progression in an Era of Progress: A Review of First- and Second-Line Treatment Options in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer. Oncologist [print-electronic]. 2016 Apr 4/6/2016; PMID: 27053502, PII: theoncologist.2015-0396, DOI: 10.1634/theoncologist.2015-0396, ISSN: 1549-490X.

Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Dilling TJ, Dobelbower MC, Govindan R, Hennon M, Horn L, Jahan TM, Komaki R, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Sharma N, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016. J Natl Compr Canc Netw. 2016 Mar; 14(3): 255-64. PMID: 26957612, PII: 14/3/255, ISSN: 1540-1413.

Hames ML, Chen H, Iams W, Aston J, Lovly CM, Horn L. Correlation between KRAS mutation status and response to chemotherapy in patients with advanced non-small cell lung cancer¿. Lung Cancer [print-electronic]. 2016 Feb; 92: 29-34. PMID: 26775593, PII: S0169-5002(15)30100-8, DOI: 10.1016/j.lungcan.2015.11.004, ISSN: 1872-8332.

Karlovich CA, Goldman J, Sun JM, Mann E, Sequist LV, Konopa K, Wen W, Angenendt P, Horn L, Spigel DR, Soria JC, Solomon B, Camidge DR, Gadgeel SM, Paweletz CP, Wu L, Chien S, O'Donnell P, Matheny S, Despain D, Rolfe L, Raponi M, Allen AR, Park K, Wakelee HA. Assessment of EGFR mutation status in matched plasma and tumor tissue of NSCLC patients from a phase 1 study of rociletinib (CO-1686). Clin. Cancer Res [print-electronic]. 2016 Jan 1/8/2016; PMID: 26747242, PII: 1078-0432.CCR-15-1260, DOI: 10.1158/1078-0432.CCR-15-1260, ISSN: 1078-0432.

Kanz BA, Pollack MH, Johnpulle R, Puzanov I, Horn L, Morgans A, Sosman JA, Rapisuwon S, Conry RM, Eroglu Z, Johnson DB. Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction. J Immunother Cancer. 2016; 4: 60. PMID: 27777770, PMCID: PMC5067899, PII: 166, DOI: 10.1186/s40425-016-0166-5, ISSN: 2051-1426.

Castellanos EH, Horn L. Immunotherapy in Lung Cancer. Cancer Treat. Res. 2016; 170: 203-23. PMID: 27535396, DOI: 10.1007/978-3-319-40389-2_10, ISSN: 0927-3042.

Damp JB, Dewey CM, Wells Q, Horn L, Kroop SF, Mendes L. Faculty Development on Clinical Teaching Skills: An Effective Model for the Busy Clinician. J Med Educ Curric Dev. 2016 Jan; 3: PMID: 29349327, PMCID: PMC5757630, PII: 10.4137_JMECD.S40798, DOI: 10.4137/JMECD.S40798, ISSN: 2382-1205.

Kroop SF, Chung CP, Davidson MA, Horn L, Damp JB, Dewey C. Rheumatologic skills development: what are the needs of internal medicine residents?. Clin. Rheumatol [print-electronic]. 2015 Dec 12/23/2015; PMID: 26694057, PII: 10.1007/s10067-015-3150-4, DOI: 10.1007/s10067-015-3150-4, ISSN: 1434-9949.

Castellanos EH, Chen SC, Drexler H, Horn L. Making the Grade: The Impact of Low-Grade Toxicities on Patient Preference for Treatment With Novel Agents. J Natl Compr Canc Netw. 2015 Dec; 13(12): 1490-5. PMID: 26656518, PII: 13/12/1490, ISSN: 1540-1413.

Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhäufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crinò L, Blumenschein GR, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N. Engl. J. Med [print-electronic]. 2015 Oct 10/22/2015; 373(17): 1627-39. PMID: 26412456, DOI: 10.1056/NEJMoa1507643, ISSN: 1533-4406.

Castellanos EH, Horn L. Generations of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Perils and Progress. Curr Treat Options Oncol. 2015 Oct; 16(10): 51. PMID: 26364032, PII: 10.1007/s11864-015-0365-1, DOI: 10.1007/s11864-015-0365-1, ISSN: 1534-6277.

, Dewey CM, Turner TL, Perkowski L, Bailey J, Gruppen LD, Riddle J, Singhal G, Mullan P, Poznanski A, Pillow T, Robins LS, Rougas SC, Horn L, Ghulyan MV, Simpson D. Twelve tips for developing, implementing, and sustaining medical education fellowship programs: Building on new trends and solid foundations. Med Teach [print-electronic]. 2015 Sep 9/23/2015; 1-9. PMID: 26398270, DOI: 10.3109/0142159X.2015.1056518, ISSN: 1466-187X.

Castellanos EH, Rivera G, Wakelee H, Horn L. Overcoming Resistance Without the Risk of Reaction: Use of Afatinib and Panitumumab in Two Cases of Epidermal Growth Factor Receptor--Mutated Non--Small-Cell Lung Cancer With T790M Mutations. Clin Lung Cancer [print-electronic]. 2015 Sep; 16(5): e97-9. PMID: 25842367, PII: S1525-7304(15)00058-3, DOI: 10.1016/j.cllc.2015.02.005, ISSN: 1938-0690.

Gettinger SN, Horn L, Gandhi L, Spigel DR, Antonia SJ, Rizvi NA, Powderly JD, Heist RS, Carvajal RD, Jackman DM, Sequist LV, Smith DC, Leming P, Carbone DP, Pinder-Schenck MC, Topalian SL, Hodi FS, Sosman JA, Sznol M, McDermott DF, Pardoll DM, Sankar V, Ahlers CM, Salvati M, Wigginton JM, Hellmann MD, Kollia GD, Gupta AK, Brahmer JR. Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. J. Clin. Oncol [print-electronic]. 2015 Jun 6/20/2015; 33(18): 2004-12. PMID: 25897158, PMCID: PMC4672027, PII: JCO.2014.58.3708, DOI: 10.1200/JCO.2014.58.3708, ISSN: 1527-7755.

Shyr Y, Horn L, Berry L. Are We Making Progress in Lung Cancer Using Progression-Free Survival as a Surrogate End Point?. JAMA Oncol. 2015 May; 1(2): 202-3. PMID: 26181024, PII: 2196177, DOI: 10.1001/jamaoncol.2015.0407, ISSN: 2374-2445.

Horn L. Targeted/emerging therapies for metastatic non-small cell lung cancer. J Natl Compr Canc Netw. 2015 May; 13(5 Suppl): 676-8. PMID: 25995428, PII: 13/5S/676, ISSN: 1540-1413.

Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Dilling TJ, Dobelbower MC, Govindan R, Grannis FW, Horn L, Jahan TM, Komaki R, Krug LM, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Schild SE, Shapiro TA, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M, . Non-Small Cell Lung Cancer, Version 6.2015. J Natl Compr Canc Netw. 2015 May; 13(5): 515-24. PMID: 25964637, PII: 13/5/515.

Lammers PE, Lu B, Horn L, Shyr Y, Keedy V. Nab-Paclitaxel in Combination With Weekly Carboplatin With Concurrent Radiotherapy in Stage III Non-Small Cell Lung Cancer. Oncologist [print-electronic]. 2015 May; 20(5): 491-2. PMID: 25845992, PMCID: PMC4425395, PII: theoncologist.2015-0030, DOI: 10.1634/theoncologist.2015-0030, ISSN: 1549-490X.

Jänne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, Ahn MJ, Kim SW, Su WC, Horn L, Haggstrom D, Felip E, Kim JH, Frewer P, Cantarini M, Brown KH, Dickinson PA, Ghiorghiu S, Ranson M. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N. Engl. J. Med. 2015 Apr 4/30/2015; 372(18): 1689-99. PMID: 25923549, DOI: 10.1056/NEJMoa1411817, ISSN: 1533-4406.

Yu HA, Sima CS, Shen R, Kass S, Gainor J, Shaw A, Hames M, Iams W, Aston J, Lovly CM, Horn L, Lydon C, Oxnard GR, Kris MG, Ladanyi M, Riely GJ. Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas. J Thorac Oncol. 2015 Mar; 10(3): 431-7. PMID: 25415430, PMCID: PMC4479120, DOI: 10.1097/JTO.0000000000000432, ISSN: 1556-1380.

Rizvi NA, Mazières J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, Horn L, Lena H, Minenza E, Mennecier B, Otterson GA, Campos LT, Gandara DR, Levy BP, Nair SG, Zalcman G, Wolf J, Souquet PJ, Baldini E, Cappuzzo F, Chouaid C, Dowlati A, Sanborn R, Lopez-Chavez A, Grohe C, Huber RM, Harbison CT, Baudelet C, Lestini BJ, Ramalingam SS. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol [print-electronic]. 2015 Mar; 16(3): 257-65. PMID: 25704439, PII: S1470-2045(15)70054-9, DOI: 10.1016/S1470-2045(15)70054-9, ISSN: 1474-5488.

Gilbert J, Chew H, Dewey C, Horn L. Medical education: perils and progress in educating and assessing a new generation of learners. Am Soc Clin Oncol Educ Book. 2015; 33-9. PMID: 25993139, PII: 00115000033, DOI: 10.14694/EdBook_AM.2015.35.33, ISSN: 1548-8756.

Morgensztern D, Campo MJ, Dahlberg SE, Doebele RC, Garon E, Gerber DE, Goldberg SB, Hammerman PS, Heist RS, Hensing T, Horn L, Ramalingam SS, Rudin CM, Salgia R, Sequist LV, Shaw AT, Simon GR, Somaiah N, Spigel DR, Wrangle J, Johnson D, Herbst RS, Bunn P, Govindan R. Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol. 2015 Jan; 10(1 Suppl 1): S1-63. PMID: 25535693, PMCID: PMC4346098, PII: 01243894-201501001-00001, DOI: 10.1097/JTO.0000000000000405, ISSN: 1556-1380.

Johnson DB, Rioth MJ, Horn L. Immune checkpoint inhibitors in NSCLC. Curr Treat Options Oncol. 2014 Dec; 15(4): 658-69. PMID: 25096781, PMCID: PMC4216599, DOI: 10.1007/s11864-014-0305-5, ISSN: 1534-6277.

Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014 Nov 11/27/2014; 515(7528): 563-7. PMID: 25428504, PII: nature14011, DOI: 10.1038/nature14011, ISSN: 1476-4687.

Janjigian YY, Smit EF, Groen HJ, Horn L, Gettinger S, Camidge DR, Riely GJ, Wang B, Fu Y, Chand VK, Miller VA, Pao W. Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations. Cancer Discov [print-electronic]. 2014 Sep; 4(9): 1036-45. PMID: 25074459, PMCID: PMC4155006, PII: 2159-8290.CD-14-0326, DOI: 10.1158/2159-8290.CD-14-0326, ISSN: 2159-8290.

Lovly CM, McDonald NT, Chen H, Ortiz-Cuaran S, Heukamp LC, Yan Y, Florin A, Ozretic L, Lim D, Wang L, Chen Z, Chen X, Lu P, Paik PK, Shen R, Jin H, Buettner R, Ansén S, Perner S, Brockmann M, Bos M, Wolf J, Gardizi M, Wright GM, Solomon B, Russell PA, Rogers TM, Suehara Y, Red-Brewer M, Tieu R, de Stanchina E, Wang Q, Zhao Z, Johnson DH, Horn L, Wong KK, Thomas RK, Ladanyi M, Pao W. Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer. Nat. Med [print-electronic]. 2014 Sep; 20(9): 1027-34. PMID: 25173427, PMCID: PMC4159407, PII: nm.3667, DOI: 10.1038/nm.3667, ISSN: 1546-170X.

Johnson DB, Dahlman KH, Knol J, Gilbert J, Puzanov I, Means-Powell J, Balko JM, Lovly CM, Murphy BA, Goff LW, Abramson VG, Crispens MA, Mayer IA, Berlin JD, Horn L, Keedy VL, Reddy NM, Arteaga CL, Sosman JA, Pao W. Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. Oncologist [print-electronic]. 2014 Jun; 19(6): 616-22. PMID: 24797823, PMCID: PMC4041676, PII: theoncologist.2014-0011, DOI: 10.1634/theoncologist.2014-0011, ISSN: 1549-490X.

Pirazzoli V, Nebhan C, Song X, Wurtz A, Walther Z, Cai G, Zhao Z, Jia P, de Stanchina E, Shapiro EM, Gale M, Yin R, Horn L, Carbone DP, Stephens PJ, Miller V, Gettinger S, Pao W, Politi K. Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1. Cell Rep [print-electronic]. 2014 May 5/22/2014; 7(4): 999-1008. PMID: 24813888, PMCID: PMC4074596, PII: S2211-1247(14)00301-5, DOI: 10.1016/j.celrep.2014.04.014, ISSN: 2211-1247.

Meador CB, Micheel CM, Levy MA, Lovly CM, Horn L, Warner JL, Johnson DB, Zhao Z, Anderson IA, Sosman JA, Vnencak-Jones CL, Dahlman KB, Pao W. Beyond histology: translating tumor genotypes into clinically effective targeted therapies. Clin. Cancer Res [print-electronic]. 2014 May 5/1/2014; 20(9): 2264-75. PMID: 24599935, PMCID: PMC4008689, PII: 1078-0432.CCR-13-1591, DOI: 10.1158/1078-0432.CCR-13-1591, ISSN: 1078-0432.

Horn L. Advances in the treatment of non-small cell lung cancer [editorial]. J Natl Compr Canc Netw. 2014 May; 12(5 Suppl): 764-7. PMID: 24853212, PII: 12/5S/764, ISSN: 1540-1413.

Shanafelt TD, Raymond M, Kosty M, Satele D, Horn L, Pippen J, Chu Q, Chew H, Clark WB, Hanley AE, Sloan J, Gradishar WJ. Satisfaction with work-life balance and the career and retirement plans of US oncologists. J. Clin. Oncol [print-electronic]. 2014 Apr 4/10/2014; 32(11): 1127-35. PMID: 24616305, PII: JCO.2013.53.4560, DOI: 10.1200/JCO.2013.53.4560, ISSN: 1527-7755.

Lammers PE, Shyr Y, Li CI, Hutchison AS, Sandler A, Carbone DP, Johnson DH, Keedy VL, Horn L. Phase II study of bendamustine in relapsed chemotherapy sensitive or resistant small-cell lung cancer. J Thorac Oncol. 2014 Apr; 9(4): 559-62. PMID: 24736081, PMCID: PMC3990869, PII: 01243894-201404000-00024, DOI: 10.1097/JTO.0000000000000079, ISSN: 1556-1380.

Gregg JR, Horn L, Davidson MA, Gilbert J. Patient enrollment onto clinical trials: the role of physician knowledge. J Cancer Educ. 2014 Mar; 29(1): 74-9. PMID: 24163050, DOI: 10.1007/s13187-013-0548-z, ISSN: 1543-0154.

Shanafelt TD, Gradishar WJ, Kosty M, Satele D, Chew H, Horn L, Clark B, Hanley AE, Chu Q, Pippen J, Sloan J, Raymond M. Burnout and career satisfaction among US oncologists. J. Clin. Oncol [print-electronic]. 2014 Mar 3/1/2014; 32(7): 678-86. PMID: 24470006, PMCID: PMC3927737, PII: JCO.2013.51.8480, DOI: 10.1200/JCO.2013.51.8480, ISSN: 1527-7755.

Horn L, Carbone DP. Reducing lung cancer mortality: 2014 update [editorial]. Semin. Oncol [print-electronic]. 2014 Feb; 41(1): 3-4. PMID: 24565576, PII: S0093-7754(13)00214-5, DOI: 10.1053/j.seminoncol.2013.12.004, ISSN: 1532-8708.

Lammers PE, Lovly CM, Horn L. A patient with metastatic lung adenocarcinoma harboring concurrent EGFR L858R, EGFR germline T790M, and PIK3CA mutations: the challenge of interpreting results of comprehensive mutational testing in lung cancer. J Natl Compr Canc Netw. 2014 Jan; 12(1): 6-11; quiz 11. PMID: 24453288, PMCID: PMC4151469, PII: 12/1/6, ISSN: 1540-1413.

Hamann HA, Lee JW, Schiller JH, Horn L, Wagner LI, Chang VT, Fisch MJ. Clinician perceptions of care difficulty, quality of life, and symptom reports for lung cancer patients: an analysis from the Symptom Outcomes and Practice patterns (SOAPP) study. J Thorac Oncol. 2013 Dec; 8(12): 1474-83. PMID: 24189514, PMCID: PMC3936653, DOI: 10.1097/01.JTO.0000437501.83763.5d, ISSN: 1556-1380.

Lammers PE, Horn L. Targeting angiogenesis in advanced non-small cell lung cancer. J Natl Compr Canc Netw. 2013 Oct 10/1/2013; 11(10): 1235-47. PMID: 24142825, PII: 11/10/1235, ISSN: 1540-1413.

Yeh P, Chen H, Andrews J, Naser R, Pao W, Horn L. DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy. Clin. Cancer Res [print-electronic]. 2013 Apr 4/1/2013; 19(7): 1894-901. PMID: 23344264, PMCID: PMC4121886, PII: 1078-0432.CCR-12-1894, DOI: 10.1158/1078-0432.CCR-12-1894, ISSN: 1078-0432.

Abramson RG, Abramson VG, Chan E, Horn L, Keedy VL, Pao W, Sosman JA. Complications of targeted drug therapies for solid malignancies: manifestations and mechanisms. AJR Am J Roentgenol. 2013 Mar; 200(3): 475-83. PMID: 23436834, PMCID: PMC3652983, PII: 200/3/475, DOI: 10.2214/AJR.12.9049, ISSN: 1546-3141.

Horn L, Keedy VL, Campbell N, Garcia G, Hayes A, Spencer B, Carbone DP, Sandler A, Johnson DH. Identifying barriers associated with enrollment of patients with lung cancer into clinical trials. Clin Lung Cancer [print-electronic]. 2013 Jan; 14(1): 14-8. PMID: 22591607, PII: S1525-7304(12)00075-7, DOI: 10.1016/j.cllc.2012.03.008, ISSN: 1938-0690.

Lovly CM, Horn L. Strategies for overcoming EGFR resistance in the treatment of advanced-stage NSCLC. Curr Treat Options Oncol. 2012 Dec; 13(4): 516-26. PMID: 22833206, DOI: 10.1007/s11864-012-0204-6, ISSN: 1534-6277.

Horn L, Koehler E, Gilbert J, Johnson DH. Factors associated with the career choices of hematology and medical oncology fellows trained at academic institutions in the United States. J. Clin. Oncol [print-electronic]. 2011 Oct 10/10/2011; 29(29): 3932-8. PMID: 21911716, PMCID: PMC3189092, PII: JCO.2011.35.8663, DOI: 10.1200/JCO.2011.35.8663, ISSN: 1527-7755.

Horn L, Zhao Z, Sandler A, Johnson D, Shyr Y, Wolff S, Devore RF, Laskin J. A phase II study of carboplatin and irinotecan in extensive stage small-cell lung cancer. Clin Lung Cancer [print-electronic]. 2011 May; 12(3): 161-5. PMID: 21663858, PII: S1525-7304(11)00014-3, DOI: 10.1016/j.cllc.2011.03.013, ISSN: 1938-0690.

Horn L, Castellanos EL, Johnson DH. Update on new drugs in small cell lung cancer. Expert Opin Investig Drugs. 2011 Apr; 20(4): 441-5. PMID: 21395484, DOI: 10.1517/13543784.2011.553185, ISSN: 1744-7658.

Horn L, Dahlberg SE, Sandler AB, Dowlati A, Moore DF, Murren JR, Schiller JH. Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. J. Clin. Oncol [print-electronic]. 2009 Dec 12/10/2009; 27(35): 6006-11. PMID: 19826110, PMCID: PMC2793043, PII: JCO.2009.23.7545, DOI: 10.1200/JCO.2009.23.7545, ISSN: 1527-7755.

Horn L, Sandler A. Epidermal growth factor receptor inhibitors and antiangiogenic agents for the treatment of non-small cell lung cancer. Clin. Cancer Res [print-electronic]. 2009 Aug 8/15/2009; 15(16): 5040-8. PMID: 19671872, PMCID: PMC3528182, PII: 1078-0432.CCR-09-0520, DOI: 10.1158/1078-0432.CCR-09-0520, ISSN: 1078-0432.

Horn L, Backlund M, Johnson DH. Targeting the eicosanoid pathway in non-small-cell lung cancer. Expert Opin. Ther. Targets [print-electronic]. 2009 Jun; 13(6): 675-88. PMID: 19409031, PMCID: PMC2891200, DOI: 10.1517/14728220902915567, ISSN: 1744-7631.

Horn L, Sandler AB. Angiogenesis in the treatment of non-small cell lung cancer. Proc Am Thorac Soc. 2009 Apr 4/15/2009; 6(2): 206-17. PMID: 19349490, PII: 6/2/206, DOI: 10.1513/pats.200807-066LC, ISSN: 1546-3222.

Horn L, Bernardo P, Sandler A, Wagner H, Levitan N, Levitt ML, Johnson DH. A phase II study of paclitaxel + etoposide + cisplatin + concurrent radiation therapy for previously untreated limited stage small cell lung cancer (E2596): a trial of the Eastern Cooperative Oncology Group. J Thorac Oncol. 2009 Apr; 4(4): 527-33. PMID: 19240650, PMCID: PMC3528175, DOI: 10.1097/JTO.0b013e31819c7daf, ISSN: 1556-1380.

Horn L, Sandler AB. Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer. Clin Lung Cancer. 2009 Mar; 10 Suppl 1: S7-16. PMID: 19362948, PMCID: PMC3528174, PII: N68174866KG23867, DOI: 10.3816/CLC.2009.s.002, ISSN: 1525-7304.

Horn L, Johnson DH. Evarts A. Graham and the first pneumonectomy for lung cancer. J. Clin. Oncol. 2008 Jul 7/1/2008; 26(19): 3268-75. PMID: 18591561, PII: 26/19/3268, DOI: 10.1200/JCO.2008.16.8260, ISSN: 1527-7755.

Horn L, Tzanetos K, Thorpe K, Straus SE. Factors associated with the subspecialty choices of internal medicine residents in Canada. BMC Med Educ. 2008; 8: 37. PMID: 18582381, PMCID: PMC2446387, PII: 1472-6920-8-37, DOI: 10.1186/1472-6920-8-37, ISSN: 1472-6920.